Neurocritical Care

, Volume 14, Issue 3, pp 475–481 | Cite as

Is Critical Illness Neuromyopathy and Duration of Mechanical Ventilation Decreased by Strict Glucose Control?

  • Luuk Wieske
  • Robin E. Harmsen
  • Marcus J. Schultz
  • Janneke Horn
Review Article

Abstract

Strict glycemic control (SGC) is reported to have a beneficial effect on critical illness polyneuropathy/myopathy (CINM) and the duration of mechanical ventilation. The methodology used to diagnose CINM differs substantially in studies on this topic. This may influence the reported treatment effect. We reviewed literature on the effect of SGC on CINM and duration of ventilation by conducting a OVID Medline systematic electronic search of literature describing effects of SGC on occurrence of CINM and the effect of SGC on the duration of mechanical ventilation. A beneficial effect of SGC on CINM, diagnosed by needle myography, was reported in three studies. One of these studies showed that the incidence of weakness or failure to wean did not decrease by SGC, as the number of electrophysiological studies (EMG) ordered for these problems remained the same. Another study reported no improvement of muscle strength due to SGC. SGC reduced the duration of mechanical ventilation in three studies while six other studies did not report this beneficial effect. SGC seems to have a beneficial effect on CINM, but the reported risk reduction is likely to be an overestimation of the treatment effect due to the diagnostic methods used. Duration of mechanical ventilation may not be a reliable surrogate marker for CINM and a beneficial effect of SGC on this parameter has not been proven. We propose to use the recently developed diagnostic criteria for ICU-acquired weakness and critical illness neuromyopathy in future studies.

Keywords

Critical illness Polyneuropathy Myopathy Insulin/therapeutic use Diagnostic accuracy Sensitivity and specificity 

References

  1. 1.
    Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, De JB, Ali NA, Sharshar T. A framework for diagnosing and classifying intensive care unit-acquired weakness. Crit Care Med. 2009;37:S299–308.PubMedCrossRefGoogle Scholar
  2. 2.
    Hermans G, De JB, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev 2009;CD006832.Google Scholar
  3. 3.
    Hermans G, Vanhorebeek I, Derde S, Van den Berghe G. Metabolic aspects of critical illness polyneuromyopathy. Crit Care Med. 2009;37:S391–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.PubMedCrossRefGoogle Scholar
  5. 5.
    Hermans G, Wilmer A, Meersseman W, Milants I, Wouters PJ, Bobbaers H, Bruyninckx F, Van den Berghe G. Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit. Am J Respir Crit Care Med. 2007;175:480–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Van den Berghe G, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology. 2005;64:1348–53.PubMedGoogle Scholar
  7. 7.
    Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359–67.PubMedCrossRefGoogle Scholar
  8. 8.
    Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van WE, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Hermans G, Schrooten M, Van DP, Berends N, Bouckaert B, De VW, Robberecht W, Van den Berghe G. Benefits of intensive insulin therapy on neuromuscular complications in routine daily critical care practice: a retrospective study. Crit Care. 2009;13:R5. doi:10.1186/cc7694.PubMedCrossRefGoogle Scholar
  10. 10.
    Annane D, Cariou A, Maxime V, Azoulay E, D’honneur G, Timsit JF, Cohen Y, Wolf M, Fartoukh M, Adrie C, Santre C, Bollaert PE, Mathonet A, Amathieu R, Tabah A, Clec’h C, Mayaux J, Lejeune J, Chevret S. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA. 2010;303:341–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Arabi YM, Dabbagh OC, Tamim HM, Al-Shimemeri AA, Memish ZA, Haddad SH, Syed SJ, Giridhar HR, Rishu AH, Al-Daker MO, Kahoul SH, Britts RJ, Sakkijha MH. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med. 2008;36:3190–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–39.PubMedCrossRefGoogle Scholar
  13. 13.
    Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hebert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97.PubMedCrossRefGoogle Scholar
  14. 14.
    De La Rosa GC, Donado JH, Restrepo AH, Quintero AM, Gonzalez LG, Saldarriaga NE, Bedoya M, Toro JM, Velasquez JB, Valencia JC, Arango CM, Aleman PH, Vasquez EM, Chavarriaga JC, Yepes A, Pulido W, Cadavid CA. Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Crit Care. 2008;12:R120.CrossRefGoogle Scholar
  15. 15.
    Preiser JC, Devos P, Ruiz-Santana S, Melot C, Annane D, Groeneveld J, Iapichino G, Leverve X, Nitenberg G, Singer P, Wernerman J, Joannidis M, Stecher A, Chiolero R. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med. 2009;35:1738–48.PubMedCrossRefGoogle Scholar
  16. 16.
    Bilotta F, Caramia R, Paoloni FP, Delfini R, Rosa G. Safety and efficacy of intensive insulin therapy in critical neurosurgical patients. Anesthesiology. 2009;110:611–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Henderson WR, Dhingra V, Chittock D, Foster D, Hebert P, Cook D, Heyland D, Dodek P, Griesdale D, Schulzer M, Ronco JJ. The efficacy and safety of glucose control algorithms in intensive care: a pilot study of the Survival Using Glucose Algorithm Regulation (SUGAR) trial. Pol Arch Med Wewn. 2009;119:439–46.PubMedGoogle Scholar
  18. 18.
    Hoedemaekers CW, Pickkers P, Netea MG, van DM, van der Hoeven JG. Intensive insulin therapy does not alter the inflammatory response in patients undergoing coronary artery bypass grafting: a randomized controlled trial [ISRCTN95608630]. Crit Care. 2005;9:R790–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Weber-Carstens S, Koch S, Spuler S, Spies CD, Bubser F, Wernecke KD, Deja M. Nonexcitable muscle membrane predicts intensive care unit-acquired paresis in mechanically ventilated, sedated patients. Crit Care Med. 2009;37:2632–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Latronico N, Shehu I, Guarneri B. Use of electrophysiologic testing. Crit Care Med. 2009;37:S316–20.PubMedCrossRefGoogle Scholar
  21. 21.
    Ali NA, O’Brien JM Jr, Hoffmann SP, Phillips G, Garland A, Finley JC, Almoosa K, Hejal R, Wolf KM, Lemeshow S, Connors AF Jr, Marsh CB. Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med. 2008;178:261–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Brunello AG, Haenggi M, Wigger O, Porta F, Takala J, Jakob SM. Usefulness of a clinical diagnosis of ICU-acquired paresis to predict outcome in patients with SIRS and acute respiratory failure. Intensive Care Med. 2010;36:66–74.PubMedCrossRefGoogle Scholar
  23. 23.
    Schultz MJ, Harmsen RE, Spronk PE. Clinical review: strict or loose glycemic control in critically ill patients—implementing best available evidence from randomized controlled trials. Crit Care. 2010;14:223.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Luuk Wieske
    • 1
    • 3
  • Robin E. Harmsen
    • 1
  • Marcus J. Schultz
    • 1
    • 2
  • Janneke Horn
    • 1
  1. 1.Department of Intensive Care MedicineAcademic Medical Centre, University of AmsterdamAmsterdamThe Netherlands
  2. 2.Laboratory for Experimental Intensive Care and AnesthesiologyAcademic Medical Centre, University of AmsterdamAmsterdamThe Netherlands
  3. 3.Department of NeurologyAcademic Medical Centre, University of AmsterdamAmsterdamThe Netherlands

Personalised recommendations